A systematic review of the current application status of decision-analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension
Abstract Background The implementation of targeted drug therapy results in a significant improvement in both survival rates and quality of life among patients diagnosed with pulmonary arterial hypertension (PAH), concurrently imposing a greater financial burden on them. The use of pharmacoeconomic e...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Cost Effectiveness and Resource Allocation |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12962-025-00621-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850202634678435840 |
|---|---|
| author | Wenxing Dong Zhe Zhang Xiaodan Wang Xiaolong Ma Mingming Chu Yulian Li Xing Xiang Cheng Peng Rong Zhang |
| author_facet | Wenxing Dong Zhe Zhang Xiaodan Wang Xiaolong Ma Mingming Chu Yulian Li Xing Xiang Cheng Peng Rong Zhang |
| author_sort | Wenxing Dong |
| collection | DOAJ |
| description | Abstract Background The implementation of targeted drug therapy results in a significant improvement in both survival rates and quality of life among patients diagnosed with pulmonary arterial hypertension (PAH), concurrently imposing a greater financial burden on them. The use of pharmacoeconomic evaluation based on decision-analytical models is extensively employed in the rational allocation of healthcare resources. Objectives The present study conducted a systematic review of the literature on the pharmacoeconomic evaluation of drugs for treating PAH, with a focus on summarizing the composition and sources of parameters in decision-analytical models. This study aims to provide methodological guidance for future economic research. Methods The review was conducted across six databases (PubMed, Embase, the Cochrane Library, CNKI, VIP, WanFang Data) and two health technology assessment agency websites (NHS EED, INAHTA). The characteristics of each study and the compositional details of the decision-analytical models are extracted. Results In total, 13 published studies were included. The pharmacoeconomic evaluation methods employed in the studies included cost-effectiveness analysis (CEA) and cost-utility analysis (CUA). The decision analysis models employed in all 13 studies were Markov models. The models were all constructed on the basis of the World Health Organization (WHO) functional class, with variations in parameter settings and sources. Conclusions All 13 Markov models provided useful insight into PAH modeling. Future research in this field can employ these research methods according to diverse research objectives. The utility values were derived from a single source; therefore, future studies should evaluate the quality of life in patients with PAH across varying disease severities. |
| format | Article |
| id | doaj-art-8a2caefabbb84d7bbdf88ba1c0042226 |
| institution | OA Journals |
| issn | 1478-7547 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Cost Effectiveness and Resource Allocation |
| spelling | doaj-art-8a2caefabbb84d7bbdf88ba1c00422262025-08-20T02:11:42ZengBMCCost Effectiveness and Resource Allocation1478-75472025-04-0123111210.1186/s12962-025-00621-zA systematic review of the current application status of decision-analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertensionWenxing Dong0Zhe Zhang1Xiaodan Wang2Xiaolong Ma3Mingming Chu4Yulian Li5Xing Xiang6Cheng Peng7Rong Zhang8Department of Pharmacy, The Second Affiliated Hospital of Army Medical UniversityDepartment of Pharmacy, The Second Affiliated Hospital of Army Medical UniversityDepartment of Pharmacy, Beidaihe Rehabilitation and Recuperation Center of Joint Logistics Support ForcesDepartment of Pharmacy, Beidaihe Rehabilitation and Recuperation Center of Joint Logistics Support ForcesDepartment of Pharmacy, The Second Affiliated Hospital of Army Medical UniversityDepartment of Pharmacy, The Second Affiliated Hospital of Army Medical UniversityDepartment of Pharmacy, The Second Affiliated Hospital of Army Medical UniversityDepartment of Pharmacy, Beidaihe Rehabilitation and Recuperation Center of Joint Logistics Support ForcesDepartment of Pharmacy, The Second Affiliated Hospital of Army Medical UniversityAbstract Background The implementation of targeted drug therapy results in a significant improvement in both survival rates and quality of life among patients diagnosed with pulmonary arterial hypertension (PAH), concurrently imposing a greater financial burden on them. The use of pharmacoeconomic evaluation based on decision-analytical models is extensively employed in the rational allocation of healthcare resources. Objectives The present study conducted a systematic review of the literature on the pharmacoeconomic evaluation of drugs for treating PAH, with a focus on summarizing the composition and sources of parameters in decision-analytical models. This study aims to provide methodological guidance for future economic research. Methods The review was conducted across six databases (PubMed, Embase, the Cochrane Library, CNKI, VIP, WanFang Data) and two health technology assessment agency websites (NHS EED, INAHTA). The characteristics of each study and the compositional details of the decision-analytical models are extracted. Results In total, 13 published studies were included. The pharmacoeconomic evaluation methods employed in the studies included cost-effectiveness analysis (CEA) and cost-utility analysis (CUA). The decision analysis models employed in all 13 studies were Markov models. The models were all constructed on the basis of the World Health Organization (WHO) functional class, with variations in parameter settings and sources. Conclusions All 13 Markov models provided useful insight into PAH modeling. Future research in this field can employ these research methods according to diverse research objectives. The utility values were derived from a single source; therefore, future studies should evaluate the quality of life in patients with PAH across varying disease severities.https://doi.org/10.1186/s12962-025-00621-zDecision-analytical modelsMarkov modelPharmacoeconomic evaluationPulmonary arterial hypertension |
| spellingShingle | Wenxing Dong Zhe Zhang Xiaodan Wang Xiaolong Ma Mingming Chu Yulian Li Xing Xiang Cheng Peng Rong Zhang A systematic review of the current application status of decision-analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension Cost Effectiveness and Resource Allocation Decision-analytical models Markov model Pharmacoeconomic evaluation Pulmonary arterial hypertension |
| title | A systematic review of the current application status of decision-analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension |
| title_full | A systematic review of the current application status of decision-analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension |
| title_fullStr | A systematic review of the current application status of decision-analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension |
| title_full_unstemmed | A systematic review of the current application status of decision-analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension |
| title_short | A systematic review of the current application status of decision-analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension |
| title_sort | systematic review of the current application status of decision analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension |
| topic | Decision-analytical models Markov model Pharmacoeconomic evaluation Pulmonary arterial hypertension |
| url | https://doi.org/10.1186/s12962-025-00621-z |
| work_keys_str_mv | AT wenxingdong asystematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT zhezhang asystematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT xiaodanwang asystematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT xiaolongma asystematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT mingmingchu asystematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT yulianli asystematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT xingxiang asystematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT chengpeng asystematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT rongzhang asystematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT wenxingdong systematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT zhezhang systematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT xiaodanwang systematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT xiaolongma systematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT mingmingchu systematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT yulianli systematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT xingxiang systematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT chengpeng systematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension AT rongzhang systematicreviewofthecurrentapplicationstatusofdecisionanalyticalmodelsinthepharmacoeconomicevaluationoftargetedtherapiesforpulmonaryarterialhypertension |